Literature DB >> 28508827

Multiple primary malignant neoplasms: A 10-year experience at a single institution from Turkey.

Durmus Etiz1, Evrim Metcalfe1, Melek Akcay1.   

Abstract

PURPOSE: The development of improved diagnostic techniques, increased survival, and life expectancy of cancer patients have all contributed to the higher frequency of multiple primary malignant neoplasms (MPMN). MPMN can be divided into two main categories: Synchronous MPMN (sMPMN) and metachronous MPMN (mMPMN).
MATERIALS AND METHODS: 122 patients with MPMN analyzed retrospectively who were admitted to the Radiation Oncology Department of Eskisehir Osmangazi University Medical Faculty from January 2004 to December 2013. The patient characteristics and relation with overall survival (OS) were examined.
RESULTS: The overall incidence of MPMN was found 1.2% in our institution. The median age was 59 (range: 29-80) years. Male:female ratio was 54.5:45.5%, and mMPMN:sMPMN ratio was 69.9:30.1%. The most common 3 cancers were head and neck (22%), breast (20%), and gastrointestinal (20%) for first primary; and gastrointestinal (22%), lung (19%), gynecologic tumors (15%) for second primary cancers, respectively. The median OS in patients with sMPMN and mMPMN were 30 (3-105) and 91 (4-493) months. 2, 3, and 5 years OS of patients with sMPMN were 86%, 75%, 63%, and with mMPMN were 92%, 88%, 80%, respectively (P < 0.005).
CONCLUSION: OS was found longer in female patients with sMPMN (P < 0.05), and in all group with mMPMN (P < 0.005).

Entities:  

Mesh:

Year:  2017        PMID: 28508827     DOI: 10.4103/0973-1482.183219

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  9 in total

1.  [Treatment and prognosis of multiple primary malignant neoplasms complicated with renal cell carcinoma].

Authors:  M Qiu; Y Y Lian; M Lu; B S Wang; X J Tian; J Lu; C Liu; S D Zhang; M Jiang; L L Ma
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

2.  Concomitant occurrence of primary renal non-Hodgkin lymphoma and a colon cancer: A rare case report.

Authors:  Ji Li; Yabin Zou; Bin Wang; Xiangwei Meng; Xun Sun
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

3.  Multiple primary malignant neoplasms: A case report and literature review.

Authors:  Linwei Zhang; Lingxin Feng; Hui Cong; Zhuang Yu; Haocheng Wang; Ya Dong; Jing Wang
Journal:  Oncol Lett       Date:  2019-08-23       Impact factor: 2.967

4.  Clinical features and survival of patients with multiple primary malignancies.

Authors:  Xin-Kun Wang; Min-Hang Zhou
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

5.  Successful Treatment of Synchronous Double Lung Primary Malignancies and Colon Cancer.

Authors:  Hosam A Alghanmi
Journal:  Cureus       Date:  2022-02-23

6.  A Descriptive Study of the Types and Survival Patterns of Saudi Patients with Multiple Primary Solid Malignancies: A 30-Year Tertiary Care Center Experience.

Authors:  Moustafa S Alhamadh; Rakan B Alanazi; Sultan T Algarni; Ahmed Abdullah R Alhuntushi; Mohammed Qasim Alshehri; Yusra Sajid Chachar; Mohammad Alkaiyat; Fouad Sabatin
Journal:  Curr Oncol       Date:  2022-07-13       Impact factor: 3.109

7.  How to prioritize treatment in dual malignancy: A case report of patient with non-Hodgkin lymphoma and breast cancer.

Authors:  Alvi Chomariyati; Muhammad Noor Diansyah; Putu Niken Ayu Amrita; Pradana Zaky Romadhon; Siprianus Ugroseno Yudho Bintoro; Ami Ashariati; Merlyna Savitri
Journal:  Ann Med Surg (Lond)       Date:  2022-07-31

8.  Cancer Prevention for Survivors: Incidence of Second Primary Cancers and Sex Differences-A Population-Based Study from an Italian Cancer Registry.

Authors:  Rosalia Ragusa; Antonina Torrisi; Alessia Anna Di Prima; Antonietta A Torrisi; Antonella Ippolito; Margherita Ferrante; Anselmo Madeddu; Vincenzo Guardabasso
Journal:  Int J Environ Res Public Health       Date:  2022-09-26       Impact factor: 4.614

9.  Survival analysis of patients with primary breast duct carcinoma and lung adenocarcinoma: a population-based study from SEER.

Authors:  Fengyuan Lv; Mingliang Cheng; Liang Jiang; Xiaoping Zhao
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.